巨星传奇(06683)公布，配售事项及认购事项已分别于2025年7月30日及2025年8月5日完成。 配售事项的所有条件均已获达成，且配售事项已于2025年7月30日完成。合共3752.45万股配售股份(占 紧随认购事项完成后公司经扩大已发行股本约4.18%)已由配售代理按配售价每股配售股份9.13港元成功 配售予不少于六名承配人。 认购事项之所有条件已获达成，而认购事项已于2025年8月5日完成。合共3752.45万股认购股份(占紧随 认购事项完成后公司经扩大已发行股本约4.18%)已配发及发行予卖方。公司将从认购事项收取所得款项 净额约3.24亿港元。 ...

Core Viewpoint - The company, Ascentage Pharma-B (06855), has entered into a placement and subscription agreement to issue up to 22 million shares at a price of HKD 68.60 per share, which represents a discount to the market price, aiming to raise approximately HKD 15.09 billion for further commercialization and development of its core products [1][2][3] Group 1: Placement and Subscription Details - The placement price of HKD 68.60 per share is approximately 8.17% lower than the closing price of HKD 74.70 on the date of the agreement [2] - The maximum number of shares to be sold represents about 6.29% of the company's existing issued share capital as of the announcement date [1] - The expected net proceeds from the subscription are estimated to be around HKD 14.93 billion, with a net price per share of approximately HKD 67.84 [2] Group 2: Use of Proceeds - Approximately 40% of the net proceeds will be allocated for commercialization efforts, including expanding coverage and improving patient access [3] - About 35% will be used for global clinical development to advance the company's core pipeline products [3] - The remaining 25% will be directed towards infrastructure and operational funding to strengthen global operations [3]